NASDAQ:SRPT Sarepta Therapeutics Q2 2025 Earnings Results & Report $16.68 +0.26 (+1.58%) Closing price 04:00 PM EasternExtended Trading$16.65 -0.03 (-0.19%) As of 04:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Sarepta Therapeutics beat analyst expectations on both earnings and revenue in its Q2 2025 results, released August 6, 2025. The company reported EPS of $2.02 versus the $0.89 consensus estimate, while revenue of $611.09 million topped the $530.66 million estimate by $80.43 million. Revenue increased 68.4% year over year. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateAugust 6, 2025TimeAfter Market ClosesConference Call4:00 PM ET Sarepta Therapeutics EPS ResultsActual EPS$2.02Consensus EPS $0.89Beat/MissBeat by +$1.13One Year Ago EPS$0.07EPS Beat Rate5 of last 8 quartersSarepta Therapeutics Revenue ResultsActual Revenue$611.09 millionExpected Revenue$530.66 millionBeat/MissBeat by +$80.43 millionYoY Revenue Growth+68.40%Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Sarepta Therapeutics Q2 2025 Earnings FAQ Did Sarepta Therapeutics beat earnings estimates for Q2 2025? Sarepta Therapeutics (NASDAQ:SRPT) reported earnings of $2.02 per share for Q2 2025, beating the consensus estimate of $0.89. The report was announced on Wednesday, August 6, 2025. What was Sarepta Therapeutics' revenue for Q2 2025? Sarepta Therapeutics reported revenue of $611.09 million for Q2 2025, against a consensus estimate of $530.66 million. Sarepta Therapeutics Earnings HeadlinesSarepta Therapeutics, Inc. 2026 Q3 - Results - Earnings Call PresentationNovember 10 at 6:35 PM | seekingalpha.comSarepta Updates High-Dose Eteplirsen Study in Duchenne Muscular DystrophyNovember 10 at 11:31 AM | tipranks.comThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.November 11 at 1:00 AM | Porter & Company (Ad)Deutsche Bank Upgrades Sarepta Therapeutics to Hold From Sell, Raises Price Target to $18 From $14November 10 at 9:15 AM | marketscreener.comMSarepta Therapeutics (NASDAQ:SRPT) Price Target Raised to $18.00November 9 at 2:54 AM | americanbankingnews.comSarepta Therapeutics, Inc. (SRPT) Q3 2026 Earnings Call TranscriptNovember 7, 2026 | seekingalpha.comSee More Sarepta Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Sarepta Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sarepta Therapeutics and other key companies, straight to your email. Email Address About Sarepta TherapeuticsSarepta Therapeutics (NASDAQ:SRPT) is a biotechnology company focused on developing genetic medicines for rare diseases, with an emphasis on Duchenne muscular dystrophy (DMD). Its research includes RNA-based treatments designed to affect how genetic instructions are processed, as well as gene therapy approaches. The company’s DMD medicines include exon-skipping therapies such as eteplirsen (Exondys 51), golodirsen (Vyondys 53) and casimersen (Amondys 45). Each is intended for patients with a specific genetic mutation and works by helping cells produce a shortened form of dystrophin, a protein affected by DMD. Sarepta is headquartered in Cambridge, Massachusetts. In addition to developing and commercializing treatments, the company conducts research into genetic medicines for other rare diseases.View Sarepta Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Keeping AI Cool: AAON Rides the AI Heatwave to Record GrowthCan Constellation Energy's Contracts Power a Stock Rebound?IonQ Raised the Bar, But 3 Quantum Rivals Face Tough QuestionsAmazon's Rally Is Outpacing Big Tech, But Can AWS Justify the AI Spending?Aehr Test Systems Notches Another Post-Earnings Win as Sales Triple on AI DemandAST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn't Going AwayPowering Up the Moon: Redwire’s $40 Million NASA Award Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
